Verified Clinical Trials Launches in Japan to Prevent Duplicate Subjects in Clinical Trials

Verified Clinical Trials (VCT) has launched in Japan in partnership with Medical Revolutions Japan (MRJ) and the Japan Association of Contract Institutes for Clinical Pharmacology (JACIC) to address duplicate and professional subjects in clinical trials. VCT's platform is widely adopted as the global standard and will be implemented in Phase I through Phase IV trials. The platform detects and prevents duplicate subjects and protocol violations at screening and maintains protections throughout the trial.

Verified Clinical Trials (VCT), a global leader in clinical trial subject registry solutions, has officially launched operations in Japan. This launch is part of a strategic partnership with Medical Revolutions Japan (MRJ) and the Japan Association of Contract Institutes for Clinical Pharmacology (JACIC) aimed at addressing the growing challenge of duplicate and professional research subjects in clinical trials [2].

The VCT platform, widely adopted as the global standard, has been selected as the best solution to replace Japan’s existing system for preventing duplicate subject registration. The new system will be implemented in Phase I through Phase IV clinical trials, providing a higher level of subject authentication and protocol compliance [2].

The VCT system offers sophisticated functionality and biometric identification capabilities, which are essential for preventing duplicate subjects and other protocol violations. This launch represents a significant step forward in ensuring the integrity and quality of clinical trials in Japan, as well as globally [2].

The partnership between VCT and MRJ, with the support of JACIC, will enable sponsors to gain a real-time tool for proactively managing protocol risk and ensuring only qualified participants are enrolled. This initiative underscores VCT's commitment to regulatory excellence and regional partnership across the APAC region [2].

The VCT system was co-founded by Mitchell Efros, MD, and Kerri Weingard, ANP, both experienced clinical researchers who developed the registry to address long-standing challenges in subject eligibility, data quality, and compliance. With dedicated team members based throughout APAC, VCT is well-positioned to support sites and sponsors locally and help elevate clinical trial quality and compliance across the region [2].

References:

[1] https://www.tradingview.com/news/reuters.com,2025-07-08:newsml_GNX4ggCj5:0-amarna-therapeutics-and-northx-biologics-finalize-agreement-to-advance-nimvec-am510-gene-therapy-toward-clinical-trials-for-type-1-diabetes/
[2] https://finance.yahoo.com/news/verified-clinical-trials-launches-japan-140600434.html